September 26, 2024 | 3rd Party Submission
Patent application: tryptamine derivatives and compositions for use in treating various diseases
View Press ReleaseSeptember 25, 2024 | 3rd Party Submission
Patent application: pharmaceutically acceptable salts of 5-MeO-DMT with X-Ray Powder Diffraction analysis
View Press ReleaseSeptember 13, 2024 | 3rd Party Submission
Patent application: synthesis of MDMA prodrugs through unscheduled intermediates
View Press ReleaseSeptember 6, 2024 | 3rd Party Submission
Patent application: combinations of tryptamines and fungal compounds to treat neuroinflammation
View Press ReleaseSeptember 3, 2024 | 3rd Party Submission
Patent application: therapeutic use of R-MDMA for stress related disorders
View Press ReleaseAugust 29, 2024 | 3rd Party Submission
Patent application: protected tryptamines for therapeutic uses including inflammation
View Press ReleaseAugust 21, 2024 | 3rd Party Submission
Patent application: transdermal delivery of psilocybin and psilocin
View Press ReleaseAugust 15, 2024 | 3rd Party Submission
Patent application: virtual reality protocols for psychedelic-assisted therapy
View Press ReleaseAugust 13, 2024 | 3rd Party Submission
Patent application: preventing suicidal ideation in patients with life-threatening diseases
View Press ReleaseAugust 2, 2024 | 3rd Party Submission
Patent application: iboga alkaloid compositions for treating neurological injuries
View Press ReleaseJuly 29, 2024 | 3rd Party Submission
Patent application: psilocybin compositions for the treatment of neurological conditions
View Press ReleaseJuly 26, 2024 | 3rd Party Submission
Patent application: psilocybin compositions for the treatment of migraine and related conditions
View Press ReleaseJuly 10, 2024 | 3rd Party Submission
Patent application: compositions of iboga alkaloids and methods of treatment
View Press ReleaseJuly 9, 2024 | 3rd Party Submission
Patent application: optimized psilocybin formulations
View Press ReleaseJune 12, 2024 | Press Release
Patent applications: vape pen to administer DMT and other psychedelics
View Press ReleaseMay 22, 2024 | Press Release
European Patent No. 3 927 337: Use of 5-MeO-DMT for Treating Major Depressive Disorder
View Press ReleaseMay 21, 2024 | 3rd Party Submission
Patent application: tryptamine derivatives and their therapeutic uses
View Press ReleaseMay 8, 2024 | 3rd Party Observation and Submission
Patent applications: psilocybin for treatment of Alcohol Use Disorder
View Press ReleaseMay 7, 2022 | 3rd Party Observation and Submission
Patent applications: subcutaneous injection of psilocybin or psilocin for treatment
View Press ReleaseMay 3, 2024 | 3rd Party Submission
Patent applications: microdosing psilocybin
View Press ReleaseApril 30, 2024 | 3rd Party Submission
Patent application: Compositions for reducing inflammation to improve or maintain mental or physical health
View Press ReleaseApril 26, 2024 | 3rd Party Submission
Patent Application: Oral encapsulations of psilocybin and psychedelic compounds
View Press ReleaseApril 24, 2024 | 3rd Party Submission
Patent Application: Psilocybin in combination with MDMA to modulate 5HT2A receptor activity
View Press ReleaseApril 16, 2024 | 3rd Party Submission
Patent application: Tryptamine combinations with 5-HT2A antagonists
View Press ReleaseApril 16, 2024 | 3rd Party Submission
Patent application: Treatment of depressive disorders with intravenous DMT compounds
View Press ReleaseApril 1, 2024 | 3rd Party Submission
Patent application: Psychedelic dosing method for treating psychiatric conditions
View Press ReleaseMarch 21, 2024 | 3rd Party Submission
Patent Application: novel safrylamine derivatives having prodrug properties
View Press ReleaseMarch 20, 2024 | 3rd Party Submission
Patent application: 5-MeO-DALT compounds
View Press ReleaseMarch 14, 2024 | 3rd Party Submission
Patent application: Desoxyscaline derivatives for changing neurotransmission
View Press ReleaseMarch 6, 2024 | 3rd Party Submission
Patent application: Intranasal administration of DMT and DMT fumarate
View Press ReleaseFebruary 21, 2024 | 3rd Party Submission
Patent Application: titrating psychedelic dosing regimen to reduce hallucination side effects
View Press ReleaseFebruary 19, 2024 | 3rd Party Submission
Patent Application: Serotonin receptor agonists for ameliorating pathogenesis
View Press ReleaseFebruary 15, 2024 | 3rd Party Submission
Patent Application: R-MDMA HCl polymorph synthesis and characterization
View Press ReleaseFebruary 14, 2024 | Press Release
Case study of the psychedelic biotech company MindMed, Inc. and patent applications that infringe on the public domain
View Press ReleaseJanuary 12, 2024 | 3rd Party Submission
Patent Application: R-MDMA enantiomer to treat broad range of disorders
View Press ReleaseJanuary 10, 2024 | 3rd Party Submission
Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD
View Press ReleaseJanuary 10, 2024 | 3rd Party Submission
Patent Application: Combination of ibogaine and antidepressant to treat psychiatric disorders
View Press ReleaseJanuary 8, 2023 | 3rd Party Submission
Patent Application: Combination of MDMA and N-acetylcysteine to Treat PTSD and mTBI
View Press ReleaseNovember 20, 2023 | 3rd Party Submission
Patent Application: composition comprising DMT and harmine
View Press ReleaseOctober 30, 2023 | 3rd Party Submission
Patent Application: methods of treatment for neurological and neuropsychiatric conditions with LSD
View Press ReleaseOctober 30, 2023 | 3rd Party Observation and Submission
Patent application: computer application for monitoring a psychedelic therapeutic session
View Press ReleaseOctober 12, 2023 | 3rd Party Submission
Patent Application: LSD for Treatment of Pain
View Press ReleaseOctober 9, 2023 | 3rd Party Submission
Patent application: transdermal delivery of psychedelics via microprojections
View Press ReleaseSeptember 20, 2023 | 3rd Party Submission
Patent application: treatment of depression with baeocystin, norbaeocystin, and psilocybin
View Press ReleaseSeptember 14, 2023 | 3rd Party Submission
Patent application: solid formulations of empathogenic compounds
View Press ReleaseSeptember 6, 2023 | 3rd Party Submission
Patent application: oral lyophilized tablet immediate release LSD formulation
View Press ReleaseSeptember 5, 2023 | 3rd Party Submission
Patent application: enhancements to psychedelic therapy safety
View Press ReleaseSeptember 1, 2023 | Application Abandoned
Patent Application: Transdermal microdosing of psychedelics
View Press ReleaseAugust 18, 2023 | 3rd Party Observation
Patent Application: Method of Producing Polymorph A’ of Psilocybin
View Press ReleaseAugust 14, 2023 | 3rd Party Observation
Patent Application: oral lyophilized tablet immediate release LSD formulation
View Press ReleaseAugust 3, 2023 | 3rd Party Submission
Patent application: norpsilocin and niacin to treat neurological disorders
View Press ReleaseJuly 31, 2023 | 3rd Party Submission
Patent application: N-acetyl-cystine and psilocybin for traumatic brain injury and/or PTSD
View Press ReleaseJuly 8, 2023 | 3rd Party Submission
Patent application: psilocybin compositions generated via tincture extraction
View Press ReleaseJuly 6, 2023 | 3rd Party Submission
Patent application: monitoring neural and physiological status while using a psychedelic
View Press ReleaseJuly 5, 2023 | 3rd Party Observation
Patent Application: LSD formulated in chewing gum
View Press ReleaseJuly 3, 2023 | Press Release
Porta Sophia Milestone: 50 Third-Party Interventions Filed
View Press ReleaseJuly 3, 2023 | 3rd Party Observation
Patent Application: method of treating pain using psychedelics
View Press ReleaseJune 22, 2023 | Application Abandoned
Patent Application: MDMA combined with Viagra® for enhanced sexual desire and ability
View Press ReleaseJune 21, 2023 | 3rd Party Observation and Submission
Patent application: LSD and psilocybin dosing system
View Press ReleaseJune 21, 2023 | 3rd Party Observation and Submission
Patent application: transdermal administration of sub-hallucinogenic dosages of psychedelics
View Press ReleaseJune 15, 2023 | Claims Rejection
Patent Application: Ibogaine Co-Administration with a Metabolism Inhibitor for Safer Therapies
View Press ReleaseJune 14, 2023 | 3rd Party Submission
Patent application: cannabidiol and psilocybin combinations to treat traumatic brain injuries
View Press ReleaseJune 14,2023 | 3rd Party Submission
Patent application: 5-MeO-DMT aerosol for inhalation
View Press ReleaseJune 12, 2022 | 3rd Party Submission
Patent application: method of providing psychedelic-assisted therapy via telehealth
View Press ReleaseJune 09, 2023 | 3rd Party Observation and Submission
Patent application: 18-methoxycoronaridine to treat obesity
View Press ReleaseJune 08, 2023 | 3rd Party Submission
Patent application: psychedelic treatment of pain
View Press ReleaseJune 07, 2023 | 3rd Party Submission
Patent application: psychedelic treatment of pain
View Press ReleaseJune 07, 2023 | 3rd Party Submission
Patent application: Immediate release D-lysergic acid diethylamide (LSD)
View Press ReleaseJune 02, 2023 | 3rd Party Observation and Submission
Patent application: 5-MeO-DMT and bufotenine to treat headache disorders
View Press ReleaseMay 26, 2023 | 3rd Party Observation and Submission
Patent application: ibogaine co-administration with a metabolism inhibitor for safer therapies
View Press ReleaseMay 23, 2023 | Claims Rejection
Patent Application: combinations of serotonergic drugs
View Press ReleaseMay 11, 2023 | 3rd Party Submission
Patent application: metered dosing formulations for psychedelics
View Press ReleaseMay 4, 2023 | 3rd Party Submission
Patent application: psilocybin to treat obesity, eating disorders, and their complications
View Press ReleaseApril 26, 2023 | 3rd Party Observation and Submission
Patent application: composition of psilocybin, psilocin, baeocystin and norpsilocin
View Press ReleaseApril 20, 2023 | Claims Rejection
Patent Application: 5HT Receptor Agonists at Sub-Hallucinogenic Levels as Neurological Treatment
View Press ReleaseApril 18, 2023 | 3rd Party Observation
Patent Application: Co-Treatment of Antidepressant and Psychedelic
View Press ReleaseApril 12, 2023 | 3rd Party Submission
Patent Application: Purified Ibogaine and Ibogaine Derivatives for the Treatment of Addiction and Depression
View Press ReleaseApril 10, 2023 | 3rd Party Submission
Patent Application: Psychedelics Taken with 5-HT2A Antagonists to Control Psychedelic Trip Duration
View Press ReleaseMarch 29, 2023 | 3rd Party Submission
Patent Application: Co-Treatment of Antidepressant and Psychedelic
View Press ReleaseMarch 16, 2023 | Claims Rejection
USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness
View Press ReleaseMarch 10, 2023 | Claims Rejection
USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness
View Press ReleaseMarch 10, 2023 | 3rd Party Submission
Patent Application: Mescaline for Treatment of Substance Use Disorders
View Press ReleaseMarch 6, 2023 | 3rd Party Submission
Patent Application: Psychedelics Combined With Lion's Mane Mushrooms and Monoamine Oxidase Inhibitors To Modulate Inflammation Caused by Infection
View Press ReleaseFebruary 23, 2023 | Claims Rejection
USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty and non-obviousness
View Press ReleaseFebruary 23, 2023 | 3rd Party Observation
Psychedelic prior art library presents four documents challenging patentability of 23 application claims
View Press ReleaseFebruary 17, 2023 | 3rd Party Submission
Psychedelic prior art library presents three documents challenging patentability of all claims
View Press ReleaseJanuary 30, 2023 | Press Release
January 23, 2023 | 3rd Party Observation
Psychedelic prior art library presents 14 documents challenging patentability of all application claims
View Press ReleaseJanuary 20, 2023 | 3rd Party Submission
Psychedelic prior art library presents 13 documents challenging patentability of all application claims
View Press ReleaseJanuary 12, 2023 | 3rd Party Submission
Psychedelic prior art library presents 26 documents challenging patentability of all claims
View Press ReleaseJanuary 6, 2023 | 3rd Party Submission
Psychedelic prior art library presents seven documents challenging patentability of all claims
View Press ReleaseDecember 15, 2022 | 3rd Party Submission
Psychedelic prior art library presents five documents challenging patentability of all claims
View Press ReleaseDecember 14, 2022 | Press Release
USPTO directly cites prior art included in Porta Sophia's third-party preissuance submission in establishing application's lack of novelty
View Press ReleaseNovember 23, 2022 | 3rd Party Submission
Psychedelic prior art library presents 10 documents challenging patentability of all application claims
View Press ReleaseNovember 23, 2022 | 3rd Party Observation
Psychedelic prior art library presents 2 documents challenging patentability of all application claims
View Press ReleaseNovember 22, 2022 | 3rd Party Observation
Psychedelic prior art library presents 4 documents challenging patentability of 38 of 52 claims
View Press ReleaseNovember 1, 2022 | 3rd Party Observation
Psychedelic prior art library presents 16 documents challenging patentability of all application claims
View Press ReleaseOctober 5, 2022 | Press Release
August 25, 2022 | Press Release
Psychedelic drug company submits revised, narrower set of claims five months after Porta Sophia's third-party preissuance submission challenged patentability
View Press ReleaseAugust 23, 2022 | 3rd Party Observation
Psychedelic prior art library presents 5 documents challenging patentability of 105 claims
View Press ReleaseJuly 22, 2022 | 3rd Party Submission
sychedelic prior art library presents 9 documents challenging patentability of all claims
View Press ReleaseJuly 22, 2022 | 3rd Party Submission
Psychedelic prior art library presents 9 documents challenging patentability of all claims
View Press ReleaseJuly 22, 2022 | 3rd Party Submission
Psychedelic prior art library presents 8 documents challenging patentability of all claims
View Press ReleaseJune 16, 2022 | 3rd Party Submission
Psychedelic prior art library presents 23 documents challenging patentability of all claims
View Press ReleaseJune 7, 2022 | 3rd Party Submission
Psychedelic prior art library presents 8 documents challenging patentability of all claims
View Press ReleaseApril 14, 2022 | 3rd Party Submission
Psychedelic prior art library presents 21 documents challenging patentability of all claims of University of Basel application
View Press ReleaseApril 5, 2022 | 3rd Party Submission
Psychedelic prior art library presents 23 documents challenging patentability of all claims of Pike Therapeutics Inc. application
View Press ReleaseMarch 9, 2022 | 3rd Party Submission
Psychedelic prior art library presents 39 documents challenging patentability of all claims of COMPASS Pathways application
View Press ReleaseFebruary 23, 2022 | 3rd Party Submission
Psychedelic prior art library presents five documents challenging patentability of all claims of the application filed by co-applicants Yale University and The United States of America as represented by the Department of Veterans Affairs
View Press ReleaseDecember 16, 2021 | 3rd Party Submission
Psychedelic drug company submits revised, narrower set of claims within a month of Porta Sophia’s third-party preissuance submission challenging patentability
View Press ReleaseNovember 19, 2021 | 3rd Party Submission
Psychedelic prior art library presents 18 documents challenging patentability of all claims of CaaMTech Inc. application
View Press ReleaseView Our Summary Chart